Marijuana Moment report
A Hawaii Senate committee last week advanced a proposal that would create a special fund to support clinical research into psychedelic-assisted treatment using substances such as psilocybin and MDMA, both of which have been granted “breakthrough therapy” status by the U.S. Food and Drug Administration (FDA).
The bill, SB 1042, from Sen. Chris Lee (D), would establish a state “mental health emerging therapies special fund,” which could be used to subsidize clinical trials, establish public-private research partnerships and eventually develop state programs around patient access for “compassionate use.”
As defined in the text of the measure, “emerging therapies” refers to psychedelic or entactogenic substances that are either approved by the FDA or under Hawaii state law as well as compounds undergoing FDA-approved clinical trials.
Read the full report
